Skip to main content

Table 3 Summary of Adverse Events (AEs)

From: Intra-articular injection of the anti-inflammatory compound LMWF-5A in adults with severe osteoarthritis: a double-blind prospective randomized controlled multi-center safety and efficacy trial

Endpoint

LMWF-5A KL grade 4 (n = 144)

LMWF-5A KL grade 2–4 (n = 1076)

Saline KL grade 2–4 (n = 931)

One or more AE

49 (34.0%)

381 (35.4%)

386 (41.5%)

One or more related AE

10 (6.9%)

11 (1.0%)

19 (2.0%)

AE by severitya

mild

25 (17.4%)

264 (24.5%)

253 (27.2%)

moderate

22 (15.3%)

162 (15.1%)

190 (20.4%)

severe

2 (1.4%)

35 (3.3%)

32 (3.4%)

Serious AE (SAE)

0 (0%)

15 (1.4%)

20 (2.1%)

AE leading to withdrawal

0 (0%)

0 (0%)

0 (0%)

AE resulting in death

0 (0%)

0 (0%)

0 (0%)

  1. aSubjects could have AEs in more than one severity category. KL, Kellgren Lawrence